Women ages 18 and older with newly diagnosed Ovarian Cancer wanted for investigational chemotherapy.
A Phase I Study of Carboplatin/Paclitaxel/CTEP-supplied agent bevacizumab and CTEP-suppolied agent ABT-888 in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer
Obstetrics & Gynecology
UVa Health System, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology seeks Women ages 18 and older with newly diagnosed ovarian, primary peritoneal or fallopian tube cancer for research study. The purpose of the study is to see if an experimental drug called ABT-888 is safe at different levels. It will be given with standard initial chemotherapy as well as a drug called bevacizumab. Study involves taking an experimental oral medicine, an experimental medicine through your vein along with standard chemotherapy and blood draws. Visits will coincide with your regular clinic appointments for treatment but may add 45 minutes to your appointment time. No compensation is provided for this study. Contact Information: For more information please contact: * Heather Lothamer * 434-924-9924, email@example.com * IRB-HSR # 14864 Principal Investigator: Linda Duska, MD